Cabozantinib

Orphan designation: Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib) Treatment of medullary thyroid carcinoma, 06/02/2009 Positive

Retrieved on: 
Wednesday, April 3, 2024
Community, Eurostat, Civil service commission, Thyroid cancer, Diagnosis, Metabolism, Diarrhea, Enzyme, Hormone, Growth, Thyroid hormones, Prevalence, Cell, Calcitonin, Disease, Patient, Malignancy, Committee, Knowledge, Tissue, Seriousness, Doxorubicin, Boulogne-Billancourt, Regulation, Cancer, EMA, IRIS, Thyroid neoplasm, Cabozantinib, Protein, Medullary thyroid cancer, Thyroid, European, COMP, Iodine, European Commission, Safety, Blood, Marketing, Human, Pharmaceutical industry

Orphan designation: Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib) Treatment of medullary thyroid carcinoma, 06/02/2009 Positive

Key Points: 


Orphan designation: Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib) Treatment of medullary thyroid carcinoma, 06/02/2009 Positive

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Retrieved on: 
Thursday, February 8, 2024
GLT, Growth, Certification, Prostate cancer, Palovarotene, Statute, Alagille syndrome, Primary biliary cholangitis, PDAC, Patient, FDA, FOP, Cabozantinib, Food, PBC, Botulinum toxin, Irinotecan, Ipsen, Phase, Acquisition, Environment, Albireo, Bank statement, Webcast, Carbon accounting, Core, Woman, Pharmaceutical industry

Ipsen ended the year with net cash of €65.1m, driven by solid free cash-flow generation of €710.9m.

Key Points: 
  • Ipsen ended the year with net cash of €65.1m, driven by solid free cash-flow generation of €710.9m.
  • Ipsen anticipates four commercial launches in 2024, following regulatory decisions for Onivyde in 1L PDAC in the U.S (H1), elafibranor in second-line PBC in the U.S. (H1) and in the E.U.
  • Ipsen has set the following financial guidance for FY 2024, which excludes any impact from potential late-stage external-innovation transactions:
    Total-sales growth greater than 6.0%, at constant currency.
  • The performance shown in this announcement covers the twelve-month period to 31 December 2023 (FY 2023) and the three-month period to 31 December 2023 (Q4 2023), compared to the twelve-month period to 31 December 2022 (FY 2022) and the three-month period to 31 December 2022 (Q4 2022), respectively, unless stated otherwise.

Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights

Retrieved on: 
Friday, December 8, 2023
Attention, Novo Nordisk, Research, Conditional sentence, AstraZeneca, Prevalence, Gene editing, Takeda Pharmaceutical Company, Proteomics, Gilead Sciences, Biotechnology, Sanofi, Bayer, Genomics, DSM-IV codes, Genetic engineering, BRD, Cas9, Inherited disorders of trafficking, Tissue engineering, GSK, Therapy, Novartis, Chronic condition, Eli Lilly and Company, Drug discovery, Cancer, GSK plc, Amgen, Growth, Pfizer, Bristol Myers Squibb, Hospital, Diabetes, Biogen, AbbVie, Drug development, Cabozantinib, Pharmaceutical industry, Generic drug, Fine chemical

Red biotechnology plays a crucial role in the development of innovative treatments and therapies for these diseases.

Key Points: 
  • Red biotechnology plays a crucial role in the development of innovative treatments and therapies for these diseases.
  • This has led to the introduction of innovative products and treatment options in the market, thereby driving the growth of the Red Biotechnology Market .
  • The market for biopharmaceuticals is expected to experience significant growth in the red biotechnology market.
  • The other applications, including animal biotechnology, environmental biotechnology, medical biotechnology, industrial biotechnology, and agricultural biotechnology, also show potential growth.

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

Retrieved on: 
Wednesday, November 29, 2023
Acquisition, Senior, GlobalData, Patient, FTD, Conference, ORR, Cancer, Pancreatic Cancer Action Network, Diagnosis, Oncology, Congress, TSX, Bristol Myers Squibb, Food, Progression-free survival, Oncolytics Biotech, ESMO, Lilly, ECIS, Afatinib, Cabozantinib, Data, Pancreatic cancer, Pelareorep, ONC, Exelixis, CAD, PFS, Drug resistance, Eli Lilly and Company, Gemcitabine, Glomus tumor, Safety, NYSE, Mirati Therapeutics, Disease, Clinical trial, Radiopharmaceutical, Death, FDA, Medical Affairs Bureau, LLY, News, Survival, Pharmaceutical industry

VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ -- USA News Group  -  According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a trend that's happening in North America too, especially among young people. Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers. Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer. Among the top developers putting out promising results with new treatments are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exelixis, Inc. (NASDAQ:EXEL), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Eli Lilly and Company (NYSE:LLY), and POINT Biopharma Global Inc. (NASDAQ:PNT).

Key Points: 
  • Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers.
  • Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer.
  • Late last year, favourable data from trials involving pelareorep in treating pancreatic cancer led to the FDA rewarding it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • By mid-2023, the Pancreatic Cancer Action Network (PanCAN) selected pelareorep for their pivotal Phase 3 trial , called Precision Promise.

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

Retrieved on: 
Wednesday, November 29, 2023
Acquisition, Senior, GlobalData, Patient, FTD, Conference, ORR, Cancer, Pancreatic Cancer Action Network, Diagnosis, Oncology, Congress, TSX, Bristol Myers Squibb, Food, Progression-free survival, Oncolytics Biotech, ESMO, Lilly, ECIS, Afatinib, Cabozantinib, Data, Pancreatic cancer, Pelareorep, ONC, Exelixis, CAD, PFS, Drug resistance, Eli Lilly and Company, Gemcitabine, Glomus tumor, Safety, NYSE, Mirati Therapeutics, Disease, Clinical trial, Radiopharmaceutical, Death, FDA, Medical Affairs Bureau, LLY, News, Survival, Pharmaceutical industry

VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ -- USA News Group  -  According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a trend that's happening in North America too, especially among young people. Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers. Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer. Among the top developers putting out promising results with new treatments are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exelixis, Inc. (NASDAQ:EXEL), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Eli Lilly and Company (NYSE:LLY), and POINT Biopharma Global Inc. (NASDAQ:PNT).

Key Points: 
  • Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers.
  • Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer.
  • Late last year, favourable data from trials involving pelareorep in treating pancreatic cancer led to the FDA rewarding it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • By mid-2023, the Pancreatic Cancer Action Network (PanCAN) selected pelareorep for their pivotal Phase 3 trial , called Precision Promise.

Royalty Pharma Reports Third Quarter 2023 Results

Retrieved on: 
Wednesday, November 8, 2023
Novartis, Aplastic anemia, Vertex, Food, N/A, Pressure, PFS, Cabozantinib, Schizophrenia, New Drug Application, Clinical trial, OS, Calendar, Sale, Exelixis, GAAP, Acquisition, Civil service commission, Apalutamide, Roche, NDA, Papillary tumors of the pineal region, Therapy, Patient, Food and Drug Administration, KarXT, European Commission, Risdiplam, Growth, Cystic fibrosis, Growth hormone, Ipsen, FDA, Progression-free survival, EBITDA, Bladder cancer, Ferring Pharmaceuticals, PTC, Multiple sclerosis, Carcinoma, PTC Therapeutics, Pharmaceutical industry, Video game, Music, Bank, Generic drug, Cryptocurrency, Adjustment, Lonapegsomatropin, Ibrutinib, Regadenoson, Cytokinetics, Nadofaragene firadenovec, Nusinersen, Elexacaftor/tezacaftor/ivacaftor

Drivers of total royalty receipts in the third quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).

Key Points: 
  • Drivers of total royalty receipts in the third quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
  • Royalty Pharma acquired the Spinraza royalty in the first quarter of 2023.
  • In September 2023, Royalty Pharma acquired a royalty interest in Skytrofa from Ascendis Pharma A/S ( press release ) for an upfront payment of $150 million.
  • During the third quarter of 2023, Royalty Pharma repurchased approximately five million shares for $144 million.

EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies

Retrieved on: 
Thursday, October 26, 2023
Neoplasm, FDA, Federal Trade Commission, HHS, Attention, Chronic inflammatory demyelinating polyneuropathy, Ovarian cancer, Frankfurt Stock Exchange, NASDAQ Biotechnology Index, Government, Obesity, Fundamental, DSM-IV codes, Alnylam Pharmaceuticals, CAH, Neurocrine, Posture, SIX Swiss Exchange, Office of Inspector General, U.S. Department of Health and Human Services, Zuranolone, Congenital adrenal hyperplasia, Biotechnology, Inflation Reduction Act of 2022, Hypertension, NBI, Amgen, NET, Depression, BB Biotech, Platinum, NAV, CIDP, Woman, FTC, Inflation, Investment, Therapy, Patient, Cabozantinib, CHF, POC, Security (finance), Rare-earth element, Public utility, Pharmaceutical industry, Bank, Vertex, Incyte, EUR, USD, Valbenazine

BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies

Key Points: 
  • BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
    The issuer is solely responsible for the content of this announcement.
  • The rise in bond yields weighed heavily on biotech stocks as well as the stock market in general.
  • BB Biotech benefited from the dollar's appreciation, but it was also exposed to the sustained selling pressure on equity markets.
  • BB Biotech traded within a narrow range during the third quarter, closing slightly higher at CHF 41.35 per share.

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

Retrieved on: 
Thursday, October 26, 2023
FDA, American Association for the Study of Liver Diseases, FY, Food, Progression-free survival, International, Heart, Hepatology, Committee, ADR, Rare disease, GMT, European Directive on Traditional Herbal Medicinal Products, CER1, Commerce, Arbitral tribunal, News, Symantec Endpoint Protection, European Medicines Agency, Alagille syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, ALGS, Cabozantinib, AB toxin, Webcast, Partnership, IPN, U.S. FDA, EMA, Primary biliary cholangitis, Committee for Medicinal Products for Human Use, Ipsen, Patient, YTD, AASLD, Fine chemical, Pharmaceutical industry, Cryptocurrency, Euronext, Neuroscience, Oncology, Odevixibat

Our portfolio has performed well across the three therapy areas, driven by strengthened commercial execution and the results of our external-innovation strategy.

Key Points: 
  • Our portfolio has performed well across the three therapy areas, driven by strengthened commercial execution and the results of our external-innovation strategy.
  • Based on the solid sales momentum, today we are confirming our guidance for the full year.
  • This was despite a positive opinion from the Committee for Medicinal Products for Human Use in July 2023.
  • The Company is planning to host a capital-markets event, starting at 12.30pm GMT on 7 December 2023 in London.

Lilly Announces Details of Presentations at ESMO Congress 2023

Retrieved on: 
Friday, October 6, 2023
Congress, Selpercatinib, Eli Lilly and Company, ID, NYSE, NSCLC, RET, Risk, Adjuvant, MTC, Lilly, The Monarch School, Triple-negative breast cancer, Recurrence, Everolimus, CEST, Oncology, ESMO, LLY, EMBER, EBC, Transfection, ET, Vandetanib, European Society for Medical Oncology, Patient, Poster, Cabozantinib, Pharmaceutical industry, Vaccine

In a late-breaking oral presentation, Lilly will share five-year results, an established benchmark for adjuvant breast cancer trials, from a preplanned interim analysis of the Phase 3 monarchE study.

Key Points: 
  • In a late-breaking oral presentation, Lilly will share five-year results, an established benchmark for adjuvant breast cancer trials, from a preplanned interim analysis of the Phase 3 monarchE study.
  • A separate poster presentation will provide data on the impact of dose reductions on efficacy for patients treated in monarchE.
  • In two late-breaking oral presentations that will be featured as part of the Presidential Symposium 1 on Saturday, October 21, Lilly will share interim analysis results from the Phase 3 LIBRETTO-431 and LIBRETTO-531 clinical studies.
  • In a mini oral presentation, Lilly will share clinical data on imlunestrant as a single agent and in combination therapy.

Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Orange, Share repurchase, District court, Investigational New Drug, Royalty payment, Patent, Checkmate, Ipilimumab, News, Software, Calendar, MSN, DC, Pharmacokinetics, Orange Book, IMDC, FDA, IND, Conference, Safety, 1836 U.S. Patent Office fire, Allele, Cabozantinib, Antibody, PIN, Webcast, Acceleration, RCC, Exelixis, OS, Trial of the century, ASCO, American Society of Clinical Oncology, ANDA, United States District Court for the Eastern District of Texas, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Douglas v. U.S. District Court ex rel Talk America, Tumor microenvironment, Society, Food, Nivolumab, Online shopping, Pharmaceutical industry, Patient

Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter ended March 31, 2023, Exelixis earned $32.7 million in royalty revenues.

Key Points: 
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter ended March 31, 2023, Exelixis earned $32.7 million in royalty revenues.
  • Cabozantinib Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO GU 2023).
  • This IND clearance triggered a $35.0 million milestone payment to Sairopa, paid in the first quarter of 2023.
  • Exelixis management will discuss the company’s financial results for the first quarter of 2023 and provide a general business update during a conference call beginning at 5:00 p.m.